109 related articles for article (PubMed ID: 8615615)
1. FK506 completely inhibits adriamycin efflux in the adriamycin-resistant strain of Ehrlich ascites tumor cells.
Asaumi J; Kawasaki S; Nishikawa K; Kuroda M; Takeda Y; Hiraki Y
Anticancer Res; 1996; 16(1):247-50. PubMed ID: 8615615
[TBL] [Abstract][Full Text] [Related]
2. Influence of metabolic inhibitors on the intracellular accumulation and retention of adriamycin.
Asaumi J; Kawasaki S; Kuroda M; Takeda Y; Kishi K; Hiraki Y
Anticancer Res; 1999; 19(1A):615-8. PubMed ID: 10226607
[TBL] [Abstract][Full Text] [Related]
3. Intracellular accumulation and retention of calcein in Ehrlich ascites tumor cells and their adriamycin-resistant strain.
Asaumi J; Kawasaki S; Kuroda M; Takeda Y; Kishi K; Hiraki Y
Anticancer Res; 1999; 19(5B):4311-4. PubMed ID: 10628392
[TBL] [Abstract][Full Text] [Related]
4. Thermosensitivity and thermotolerance in the adriamycin-resistant strain of Ehrlich ascites tumor cells.
Asaumi J; Kawasaki S; Kuroda M; Takeda Y; Hiraki Y
Anticancer Res; 1996; 16(5A):2569-73. PubMed ID: 8917353
[TBL] [Abstract][Full Text] [Related]
5. Effects of quercetin on the cell growth and the intracellular accumulation and retention of adriamycin.
Asaum J; Matsuzaki H; Kawasak S; Kuroda M; Takeda Y; Kishi K; Hiraki Y
Anticancer Res; 2000; 20(4):2477-83. PubMed ID: 10953314
[TBL] [Abstract][Full Text] [Related]
6. Influence of bovine calf serum on the intracellular accumulation and retention of adriamycin.
Asaumi J; Matsuzaki H; Kawasaki S; Kuroda M; Takeda Y; Kishi K; Hiraki Y
Anticancer Res; 2000; 20(2A):769-72. PubMed ID: 10810352
[TBL] [Abstract][Full Text] [Related]
7. Energy metabolism of adriamycin-sensitive and -resistant Ehrlich ascites tumor cells.
Miccadei S; Fanciulli M; Bruno T; Paggi MG; Floridi A
Oncol Res; 1996; 8(1):27-35. PubMed ID: 8704284
[TBL] [Abstract][Full Text] [Related]
8. Cepharanthin enhances adriamycin sensitivity by synergistically accelerating apoptosis for adriamycin-resistant osteosarcoma cell lines, SaOS2-AR and SaOS2 F-AR.
Katsui K; Kuroda M; Wang Y; Komatsu M; Himei K; Takemoto M; Akaki S; Asaumi J; Kanazawa S; Hiraki Y
Int J Oncol; 2004 Jul; 25(1):47-56. PubMed ID: 15201988
[TBL] [Abstract][Full Text] [Related]
9. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
10. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells.
Mizutani Y; Yoshida O; Miki T; Bonavida B
Clin Cancer Res; 1999 Sep; 5(9):2605-12. PubMed ID: 10499639
[TBL] [Abstract][Full Text] [Related]
11. Influence of microenvironmental pH on adriamycin resistance.
Alabaster O; Woods T; Ortiz-Sanchez V; Jahangeer S
Cancer Res; 1989 Oct; 49(20):5638-43. PubMed ID: 2790781
[TBL] [Abstract][Full Text] [Related]
12. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
[TBL] [Abstract][Full Text] [Related]
13. [Reversal of adriamycin resistance by verapamil and ligustrazini in mouse Ehrlich ascites cancer].
Hu YP; Lin J; Wang QD; Yie QX; Zhang TM
Yao Xue Xue Bao; 1993; 28(1):75-8. PubMed ID: 8328276
[TBL] [Abstract][Full Text] [Related]
14. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole.
Desai PB; Duan J; Sridhar R; Damle BD
Methods Find Exp Clin Pharmacol; 1997 May; 19(4):231-9. PubMed ID: 9228648
[TBL] [Abstract][Full Text] [Related]
15. The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo.
Majumder S; Dutta P; Mookerjee A; Choudhuri SK
Chem Biol Interact; 2006 Feb; 159(2):90-103. PubMed ID: 16289015
[TBL] [Abstract][Full Text] [Related]
16. Reversal effect of substituted 1,3-dimethyl-1H-quinoxalin-2-ones on multidrug resistance in adriamycin-resistant K562/A02 cells.
Sun LR; Li X; Cheng YN; Yuan HY; Chen MH; Tang W; Ward SG; Qu XJ
Biomed Pharmacother; 2009 Mar; 63(3):202-8. PubMed ID: 18818047
[TBL] [Abstract][Full Text] [Related]
17. Targeted adriamycin delivery to MXT-B2 metastatic mammary carcinoma cells by transferrin liposomes: effect of adriamycin ADR-to-lipid ratio.
Lopez-Barcons LA; Polo D; Llorens A; Reig F; Fabra A
Oncol Rep; 2005 Nov; 14(5):1337-43. PubMed ID: 16211306
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro.
Khdair A; Handa H; Mao G; Panyam J
Eur J Pharm Biopharm; 2009 Feb; 71(2):214-22. PubMed ID: 18796331
[TBL] [Abstract][Full Text] [Related]
19. [Status of estrogen receptor affects the drug sensitivity of drug-resistant MCF-7/Adr human breast cancer cells to droloxifene and Adriamycin].
Gao HD; Sun JZ; Bi DS; Ma R
Ai Zheng; 2003 Apr; 22(4):376-9. PubMed ID: 12703992
[TBL] [Abstract][Full Text] [Related]
20. Reversal effects of hyaluronan oligosaccharides on adriamycin resistance of K562/A02 cells.
Cui X; Zhou S; Xu H; Zhao T; Liu A; Guo X; Wang F
Anticancer Drugs; 2009 Oct; 20(9):800-6. PubMed ID: 19606017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
